{name}
{subtitle}
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~16 mi. (Chelyabinsk, Russia, +176 more cities)
facility
Chelyabinsk Regional Clinical Center Oncology and Nuclear Medicine ( Site 2644)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~16 mi. (Chelyabinsk, Russia, +383 more cities)
facility
Evimed
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~16 mi. (Chelyabinsk, Russia, +226 more cities)
facility
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 0565)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
city
~16 mi. (Chelyabinsk, Russia, +147 more cities)
facility
Chelyabinsk Regional Clinical Center Oncology and Nuclear Medicine ( Site 0741)
condition
Cervical Adenocarcinoma, +2 more conditions
drug
brachytherapy, +3 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~16 mi. (Chelyabinsk, Russia, +158 more cities)
facility
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1913)
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
city
~16 mi. (Chelyabinsk, Russia, +131 more cities)
facility
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1816)
drug
CAPOX regimen, +3 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~16 mi. (Chelyabinsk, Russia, +145 more cities)
facility
Chelyabinsk Regional Clinical Oncology Dispensary ( Site 2014)
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~16 mi. (Chelyabinsk, Russia, +105 more cities)
facility
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1212)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
city
~16 mi. (Chelyabinsk, Russia, +41 more cities)
facility
Chelyabisnk regional clinical center for oncology and nuclear medicine
condition
Fallopian Tube Carcinoma, +2 more conditions
drug
ado-trastuzumab emtansine, +5 more drugs
drug type
chemotherapy, +2 more types